 |
David Stern, Ph.D.
Professor of Pathology
Director, Graduate Studies, Department of
Pathology, Yale University
Co-Program Director of the Breast Cancer Research
Program at the Yale Comprehensive Cancer Center
B.S. Massachusetts Institute of Technology, 1976
Ph.D. University
of California, San Diego, CA, Salk
Institute 1983
Postdoctoral, Whitehead Institute
for Biomedical Research,
Massachusetts Institute of
Technology
|
|
Human carcinogenesis is driven by gene alterations
that deregulate cell proliferation, and others that disrupt checkpoint
controls. Much of the work my laboratory is devoted to a major human
oncogene, the neu/ErbB2/HER-2 receptor tyrosine kinase, which is now
a validated therapeutic target in breast cancer. We also study DNA
damage checkpoint pathways which are important in cancer causation,
since their failure triggers genomic instability. These same pathways
determine responses to genotoxic cancer therapeutics. For more
information and publications see http://myprofile.cos.com/sternd61. |
Jackson-Fisher,
A.J., Bellinger, G., Ramabhadran,
R., Morris, J.K., Lee, K.-F., and D.F. Stern. 2004. ErbB2 is Required for Ductal Morphogenesis
of the Mammary Gland. Proc.Natl.Acad.Sci
USA 101:17138-43
.
Xu, X., Lee, J., and D.F. Stern. 2004. Microcephalin is required
for the DNA damage-induced intra-S and G2/M checkpoints. J. Biol.Chem.
279:34091-34094.
*DiGiovanna, M.P. * Stern, D.F., Edgerton , S., Whalen ,
S.G., Moore II , D., and A.D. Thor. 2005. ErbB-2 Activation, Epidermal
Growth Factor Receptor Expression and Prognosis in Breast Cancer Patients.
Journal of Clinical Oncology 23:1152-60.
*authors contributed equally to this work
Li, Jia., and D.F. Stern. 2005. Regulation
of Chk2 by DNA-dependent protein
kinase. J. Biol. Chem. 280:12041-50. |
